- Home
- MYGN vs ACNB Comparison
MYGN vs ACNB Comparison
Compare MYGN & ACNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- ACNB
- Stock Information
- Founded
- MYGN 1991
- ACNB 1857
- Country
- MYGN United States
- ACNB United States
- Employees
- MYGN N/A
- ACNB N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ACNB Major Banks
- Sector
- MYGN Health Care
- ACNB Finance
- Exchange
- MYGN Nasdaq
- ACNB Nasdaq
- Market Cap
- MYGN 423.1M
- ACNB 450.1M
- IPO Year
- MYGN 1995
- ACNB N/A
- Fundamental
- Price
- MYGN $7.64
- ACNB $44.70
- Analyst Decision
- MYGN Hold
- ACNB Strong Buy
- Analyst Count
- MYGN 13
- ACNB 3
- Target Price
- MYGN $13.50
- ACNB $50.00
- AVG Volume (30 Days)
- MYGN 1.4M
- ACNB 19.2K
- Earning Date
- MYGN 11-06-2025
- ACNB 10-23-2025
- Dividend Yield
- MYGN N/A
- ACNB 3.03%
- EPS Growth
- MYGN N/A
- ACNB N/A
- EPS
- MYGN N/A
- ACNB 2.69
- Revenue
- MYGN $832,900,000.00
- ACNB $123,053,000.00
- Revenue This Year
- MYGN $0.17
- ACNB $40.40
- Revenue Next Year
- MYGN $6.19
- ACNB $4.84
- P/E Ratio
- MYGN N/A
- ACNB $16.69
- Revenue Growth
- MYGN 3.83
- ACNB 15.31
- 52 Week Low
- MYGN $3.76
- ACNB $35.70
- 52 Week High
- MYGN $29.30
- ACNB $50.72
- Technical
- Relative Strength Index (RSI)
- MYGN 75.45
- ACNB 50.73
- Support Level
- MYGN $6.73
- ACNB $44.20
- Resistance Level
- MYGN $7.05
- ACNB $45.47
- Average True Range (ATR)
- MYGN 0.38
- ACNB 0.66
- MACD
- MYGN 0.10
- ACNB -0.15
- Stochastic Oscillator
- MYGN 94.31
- ACNB 32.53
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About ACNB ACNB Corporation
ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.